Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U
Month: April 2018
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
ObsEva on page 17 of Understanding Fertility Special Report 2018
Special report in the Raconteur Article in ‘The Times’ Click here for publication link IVF ‘BREAKTHROUGH’ TREATMENT Pioneering use of…
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
(GLOBE NEWSWIRE via COMTEX) –ObsEva SA / ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs…
Annual Report 2017
ObsEva-Annual-Report-2017 (2)Download
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
Geneva, Switzerland and Boston, MA – April 16, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…